Sanguinaria canadensis, bloodroot, is a perennial, herbaceous flowering plant native to eastern North America. It is the only species in the genus Sanguinaria, included in the family Papaveraceae, and most closely related to Eomecon of eastern Asia.
Sanguinaria canadensis is also known as bloodwort, red puccoon root, and sometimes pauson. It has also been known as tetterwort in the US, although that name is used in Britain to refer to Chelidonium majus. Plants are variable in leaf and flower shape and have in the past been separated out as different subspecies due to these variable shapes. Currently most taxonomic treatments lump these different forms into one highly variable species. In bloodroot, the juice is red and poisonous.
Sanguinaria canadensis, is a variable species growing from 20–50 centimetres (7.9–20 in) tall, normally with one large, sheath-like basal multi-lobed leaf up to 12 centimetres (4.7 in) across. Bloodroot stores sap in an orange colored rhizome, that grows shallowly under or at the soil surface. Over many years of growth, the branching rhizome can grow into a large colony. Plants start to bloom before the foliage unfolds in early spring and after blooming the leaves expand to their full size and go summer dormant in mid to late summer.
The flowers are produced from March to May, with 8-12 delicate white petals and yellow reproductive parts. The flowers appear over clasping leaves while blooming. The flowers are pollinated by small bees and flies, seeds develop in elongated green pods 40 to 60 mm in length and ripen before the foliage goes dormant. The seeds are round in shape and when ripe are black to orange-red in color.
Distribution and habitat
Sanguinaria canadensis plants are found growing in moist to dry woods and thickets, often on flood plains and near shores or streams on slopes. They grow less frequently in clearings and meadows or on dunes, and are rarely found in disturbed sites. Deer will feed on the plants in early spring.
Bloodroot is one of many plants whose seeds are spread by ants, a process called myrmecochory. The seeds have a fleshy organ called an elaiosome that attracts ants. The ants take the seeds to their nest, where they eat the elaiosomes, and put the seeds in their nest debris, where they are protected until they germinate. They also get the added bonus of growing in a medium made richer by the ant nest debris.
Sanguinaria canadensis is cultivated as an ornamental plant. The double flowering forms are prized by gardeners for their large showy white flowers, which are produced very early in the gardening season. Bloodroot flower petals are shed within a day or two of pollination so the flower display is short lived. The double forms bloom much longer than the normal forms, the double flowers are made up of stamens that have been changed into petal looking like parts, making pollination more difficult.
Bloodroot produces benzylisoquinoline alkaloids, primarily the toxin sanguinarine. The alkaloids are transported to and stored in the rhizome. Comparing the biosynthesis of morphine and sanguinarine, the final intermediate in common is (S)-reticuline. A number of plants in Papaveraceae and Ranunculaceae, as well as plants in the genus Colchicum (family Colchicaceae) and genus Chondodendron (family Menispermaceae), also produce such benzylisoquinoline alkaloids.
Plant geneticists have identified and sequenced genes which produce the enzymes required for this production. One enzyme involved is CYP80B1, which produces (S)-3'-hydroxy-N-methylcoclaurine and mendococlaurine from (S)-N-methylcoclaurine.
Toxicity to animal cells
Sanguinarine kills animal cells by blocking the action of Na+/K+-ATPase transmembrane proteins. As a result, applying bloodroot to the skin may destroy tissue and lead to the formation of a large scab, called an eschar. Bloodroot and its extracts are thus considered escharotic.
Internal use is inadvisable. Applying escharotic agents, including bloodroot, to the skin is sometimes suggested as a home treatment for skin cancer, these attempts can be severely disfiguring. Salves derived from bloodroot cannot be relied on to remove an entire malignant tumor. Microscopic tumor deposits may remain after visible tumor tissue is burned away, and case reports have shown that in such instances tumor has recurred and/or metastasized.
Numerous published, pre-clinical In Vitro and In Vivo studies have demonstrated that sanguinarine causes targeted apoptosis in human cancer cells, and recommend future development of sanguinarine as a potential cancer treatment.[non-primary source needed][non-primary source needed][non-primary source needed][non-primary source needed][non-primary source needed] A study conducted by the Case Western Reserve University in 2000 found that low doses of sanguinarine caused this apoptosis in cancerous human epidermoid carcinoma cells while little reaction from normal human skin cells was observed.[non-primary source needed]
Complementary and alternative medicine
In physician William Cook's 1869 work The Physiomedical Dispensatory is recorded a chapter on the uses and preparations of bloodroot, which described tinctures and extractions, and also included at least the following cautionary report:
The U. S. Dispensatory says four persons lost their lives at Bellevue Hospital, New York, by drinking largely of blood root tincture in mistake for ardent spirits [...]
Greater Celandine (Chelidonium majus), a member of the Poppy family (Papaveraceae) was used in Colonial America as a wart remedy. Bloodroot has been similarly applied in the past. This may explain the multiple American and British definitions of "Tetterwort" in 1913.
Bloodroot extracts have also been promoted by some supplement companies as a treatment or cure for cancer, but the U.S. Food and Drug Administration has listed some of these products among its "187 Fake Cancer 'Cures' Consumers Should Avoid". Indeed, far from curing cancer, products containing bloodroot are strongly associated with the development of oral leukoplakia, which is a premalignant lesion that may develop into oral cancer.
Commercial uses of sanguinarine and bloodroot extract include dental hygiene products. The United States FDA has approved the inclusion of sanguinarine in toothpastes as an antibacterial or anti-plaque agent.[non-primary source needed][non-primary source needed] However, the use of sanguinaria in oral hygiene products is associated with the development of oral leukoplakia, a premalignant lesion which may develop into oral cancer. On 24 Nov 2003, the Colgate-Palmolive Company of Piscataway, New Jersey, United States commented by memorandum to the United States Food and Drug Administration that then-proposed rules for levels of sanguinarine in mouthwash and dental wash products were lower than necessary. However, this conclusion is controversial.
Some animal food additives sold and distributed in Europe such as Phytobiotics' Sangrovit contain sanguinarine and chelerythrine. On 14 May 2003, Cat Holmes reported in Georgia Faces that Jim Affolter and Selima Campbell, horticulturists at the University of Georgia College of Agricultural and Environmental Sciences, were meeting with Phytobiotics to relate their research into commercial cultivation of bloodroot.
Bloodroot is a popular red natural dye used by Native American artists, especially among southeastern rivercane basketmakers. The blood of the root (when cut open) was used as a dye. A break in the surface of the plant, especially the roots, reveals a reddish sap.
- "Bloodroot Wildflowers".
- Alcantara, Joenel; Bird, David A.; Franceschi, Vincent R.; Facchini, Peter J. (2005). "Sanguinarine Biosynthesis is Associated with the Endoplasmic Reticulum in Cultured Opium Poppy Cells after Elicitor Treatment". Plant Physiology 138 (1): 173–83. doi:10.1104/pp.105.059287. JSTOR 4629815. PMC 1104173. PMID 15849302.
- KEGG PATHWAY: Alkaloid biosynthesis I - Reference pathway
- KEGG ENZYME: 18.104.22.168
- Don't Use Corrosive Cancer Salves (Escharotics), Stephen Barrett, M.D.
- McDaniel, S.; Goldman, GD (2002). "Consequences of Using Escharotic Agents as Primary Treatment for Nonmelanoma Skin Cancer". Archives of Dermatology 138 (12): 1593–6. doi:10.1001/archderm.138.12.1593. PMID 12472348.
- Aburai, Nobuhiro; Yoshida, Mami; Ohnishi, Motoko; Kimura, Ken-Ichi (2010). "Sanguinarine as a Potent and Specific Inhibitor of Protein Phosphatase 2C in Vitro and Induces Apoptosis via Phosphorylation of p38 in HL60 Cells". Bioscience, Biotechnology, and Biochemistry 74 (3): 548–52. doi:10.1271/bbb.90735. PMID 20208361.
- Weerasinghe, Priya; Hallock, Sarathi; Brown, Robert E.; Loose, David S.; Buja, L. Maximilian (2012). "A model for cardiomyocyte cell death: Insights into mechanisms of oncosis". Experimental and Molecular Pathology. doi:10.1016/j.yexmp.2012.04.022. PMID 22609242.
- Adhami, VM; Aziz, MH; Mukhtar, H; Ahmad, N (2003). "Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes". Clinical cancer research 9 (8): 3176–82. PMID 12912970.
- Sun, Meng; Lou, Wei; Chun, Jae Yeon; Cho, Daniel S.; Nadiminty, Nagalakshmi; Evans, Christopher P. et al. (2010). "Sanguinarine Suppresses Prostate Tumor Growth and Inhibits Survivin Expression". Genes & Cancer 1 (3): 283–92. doi:10.1177/1947601910368849. PMC 3036540. PMID 21318089.
- Holy, Jon; Lamont, Genelle; Perkins, Edward (2006). "Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine". BMC Cell Biology 7: 13. doi:10.1186/1471-2121-7-13. PMC 1444914. PMID 16512916.
- Malikovaa, Jana; Zdarilova, Adela; Hlobilkova, Alice (2006). "Effects of sanguinarine and chelerythrine on the cell cycle and apoptosis". Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 150 (1): 5–12. PMID 16936897.
- Ahmad, Nihal; Gupta, Sanjay; Husain, Mirza M.; Heiskanen, Kaisa M.; Mukhtar, Hasan (2000). "Differential Antiproliferative and Apoptotic Response of Sanguinarine for Cancer Cells versus Normal Cells". Clinical Cancer Research 6 (4): 1524–8. PMID 10778985.
- Native American Ethnobotany (University of Michigan - Dearborn: Sanguinaria canadensis' . accessed 12.1.2011
- Sanguinaria Canadensis. | Henriette's Herbal Homepage
- "187 Fake Cancer "Cures" Consumers Should Avoid". United States Food and Drug Administration. Retrieved 2010-04-15.
- Bouquot, Brad W. Neville , Douglas D. Damm, Carl M. Allen, Jerry E. (2002). Oral & maxillofacial pathology (2. ed. ed.). Philadelphia: W.B. Saunders. p. 338. ISBN 0721690033.
- Godowski, KC (1989). "Antimicrobial action of sanguinarine". The Journal of clinical dentistry 1 (4): 96–101. PMID 2700895.
- Southard, GL; Boulware, RT; Walborn, DR; Groznik, WJ; Thorne, EE; Yankell, SL (1984). "Sanguinarine, a new antiplaque agent: Retention and plaque specificity". Journal of the American Dental Association 108 (3): 338–41. PMID 6585404.
- How to Report Problems With Products Regulated by FDA
- Kuftinec, MM; Mueller-Joseph, LJ; Kopczyk, RA (1990). "Sanguinaria toothpaste and oral rinse regimen clinical efficacy in short- and long-term trials". Journal of the Canadian Dental Association 56 (7 Suppl): 31–3. PMID 2207852.
- Leukoplakia, (pdf format) hosted by the American Academy of Oral and Maxillofacial Pathology. Page accessed on December 19, 2006.
- Letter to FDA, Collgate-Palmolive Company, 24 Nov. 2003
- Letter to FDA, Professor George T. Gallagher, Boston University Goldman School of Dental Medicine, 23 June 2003.
- Georgia FACES
- Nolan, Justin. "Northeast Oklahoma, USA." Society of Ethnobotany. 2007 (retrieved 9 Jan 2011)
Double-flowered cultivars such as S. canadensis forma multiplex are popular with gardeners, as their flowers last longer than single ones
|Wikimedia Commons has media related to: Sanguinaria canadensis|
- USDA Plants Profile: Sanguinaria canadensi (Bloodroot)
- Flora of North America: Flora profile of Sanguinaria canadensi
- Flora of North America: Distribution map
- CT Botanical Society - Sanguinaria canadensi photographs and information
- Floridanature.org: Bloodroot pictures and information
- KEGG (Kyoto Encyclopedia of Genes and Genomes) - Alkaloid biosynthesis I - Reference pathway